Organon & Co. (OGN) 10-Q 1 Nov 24 2024 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2024	Oct. 25, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	001-40235
Entity Registrant Name	Organon & Co.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-4838035
Entity Address, Address Line One	30 Hudson Street, Floor 33
Entity Address, City or Town	Jersey City,
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07302
City Area Code	(551)
Local Phone Number	430-6900
Title of 12(b) Security	Common Stock ($0.01 par value)
Trading Symbol	OGN
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		257,538,875
Entity Central Index Key	0001821825
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income - USD ($) shares in Thousands, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Revenues	$ 1,582	$ 1,519	$ 4,811	$ 4,665
Cost of sales	659	612	1,992	1,832
Gross profit	923	907	2,819	2,833
Selling, general and administrative	422	538	1,290	1,424
Research and development	111	137	339	394
Acquired in-process research and development and milestones	51	0	81	8
Restructuring costs	0	0	23	4
Interest expense	126	134	388	398
Exchange losses	6	14	11	25
Other expense, net	0	4	9	11
Income before income taxes	207	80	678	569
Income tax (benefit) expense	(152)	22	(77)	92
Net income	$ 359	$ 58	$ 755	$ 477
Earnings per share:
Basic (in dollars per share)	$ 1.39	$ 0.23	$ 2.94	$ 1.87
Diluted (in dollars per share)	$ 1.38	$ 0.23	$ 2.92	$ 1.86
Weighted average shares outstanding:
Basic (in shares)	257,498	255,588	256,830	255,112
Diluted (in shares)	259,757	256,349	258,908	256,162

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Statement of Comprehensive Income [Abstract]
Net income	$ 359	$ 58	$ 755	$ 477
Other Comprehensive Income (Loss), Net of Taxes:
Benefit plan net (loss) gain and prior service credit, net of amortization	(1)	0	0	(1)
Cumulative translation adjustment	42	(43)	(30)	(11)
Other comprehensive income (loss)	41	(43)	(30)	(12)
Comprehensive income	$ 400	$ 15	$ 725	$ 465

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 763	$ 693
Accounts receivable (net of allowance for doubtful accounts of $13 in 2024 and $9 in 2023)	1,685	1,744
Inventories (excludes inventories of $130 in 2024 and $110 in 2023 classified in Other assets)	1,383	1,315
Other current assets	925	756
Total Current Assets	4,756	4,508
Property, plant and equipment, net	1,204	1,183
Goodwill	4,603	4,603
Intangibles, net	763	533
Other assets	1,426	1,231
Total Assets	12,752	12,058
Current Liabilities:
Current portion of long-term debt	10	9
Trade accounts payable	1,092	1,314
Accrued and other current liabilities	1,458	1,389
Income taxes payable	230	206
Total Current Liabilities	2,790	2,918
Long-term debt	8,739	8,751
Deferred income taxes	56	47
Other noncurrent liabilities	674	412
Total Liabilities	12,259	12,128
Contingencies (Note 15)
Organon & Co. Stockholders’ Equity (Deficit):
Common stock, $0.01 par value Authorized - 500,000 Issued and outstanding - 257,539 in 2024 and 255,626 in 2023	3	3
Additional paid-in capital	86	25
Retained earnings	975	443
Accumulated other comprehensive loss	(571)	(541)
Total Stockholders’ Equity (Deficit)	493	(70)
Total Liabilities and Stockholders’ Equity (Deficit)	$ 12,752	$ 12,058

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 13	$ 9
Inventories classified in other assets	$ 130	$ 110
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	500,000,000	500,000,000
Common stock, issued (in shares)	257,539,000	255,626,000
Common stock, outstanding (in shares)	257,539,000	255,626,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Millions	Total	Common Stock	Additional Paid-In Capital	Retained Earnings and (Accumulated Deficit)	Accumulated Other Comprehensive Income (Loss)
Beginning balance (in shares) at Dec. 31, 2022		254,370,000
Beginning balance at Dec. 31, 2022	$ (892)	$ 3	$ 0	$ (331)	$ (564)
Stockholders' Equity [Roll Forward]
Net income	477			477
Other comprehensive income (loss), net of taxes	(12)				(12)
Cash dividends declared on common stock	(221)			(221)
Stock-based compensation plans and other (in shares)		1,236,000
Stock-based compensation plans and other	59			59
Ending balance (in shares) at Sep. 30, 2023		255,606,000
Ending balance at Sep. 30, 2023	(589)	$ 3	0	(16)	(576)
Beginning balance (in shares) at Jun. 30, 2023		255,568,000
Beginning balance at Jun. 30, 2023	(555)	$ 3	0	(25)	(533)
Stockholders' Equity [Roll Forward]
Net income	58			58
Other comprehensive income (loss), net of taxes	(43)				(43)
Cash dividends declared on common stock	(74)			(74)
Stock-based compensation plans and other (in shares)		38,000
Stock-based compensation plans and other	25			25
Ending balance (in shares) at Sep. 30, 2023		255,606,000
Ending balance at Sep. 30, 2023	(589)	$ 3	0	(16)	(576)
Beginning balance (in shares) at Dec. 31, 2023		255,626,000
Beginning balance at Dec. 31, 2023	(70)	$ 3	25	443	(541)
Stockholders' Equity [Roll Forward]
Net income	755			755
Other comprehensive income (loss), net of taxes	(30)				(30)
Cash dividends declared on common stock	(223)			(223)
Stock-based compensation plans and other (in shares)		1,913,000
Stock-based compensation plans and other	61		61
Ending balance (in shares) at Sep. 30, 2024		257,539,000
Ending balance at Sep. 30, 2024	493	$ 3	86	975	(571)
Beginning balance (in shares) at Jun. 30, 2024		257,473,000
Beginning balance at Jun. 30, 2024	144	$ 3	63	690	(612)
Stockholders' Equity [Roll Forward]
Net income	359			359
Other comprehensive income (loss), net of taxes	41				41
Cash dividends declared on common stock	(74)			(74)
Stock-based compensation plans and other (in shares)		66,000
Stock-based compensation plans and other	23		23
Ending balance (in shares) at Sep. 30, 2024		257,539,000
Ending balance at Sep. 30, 2024	$ 493	$ 3	$ 86	$ 975	$ (571)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Statement of Stockholders' Equity [Abstract]
Common stock dividends declared (in dollars per share)	$ 0.28	$ 0.28	$ 0.84	$ 0.84

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash Flows from Operating Activities
Net income	$ 755	$ 477
Adjustments to reconcile net income to net cash flows provided by operating activities:
Depreciation	98	88
Amortization	102	88
Acquired in-process research and development and milestones	81	8
Deferred income tax (benefit) expense	(170)	4
Stock-based compensation	79	74
Unrealized foreign exchange (gain) loss	(24)	19
Other	18	24
Net changes in assets and liabilities
Accounts receivable	42	(185)
Inventories	(100)	(137)
Other current assets	(180)	(56)
Trade accounts payable	(215)	(68)
Accrued and other current liabilities	(28)	34
Income taxes payable	24	(21)
Other	67	53
Net Cash Flows Provided by Operating Activities	549	402
Cash Flows from Investing Activities
Capital expenditures	(120)	(172)
Proceeds from sale of property, plant and equipment	2	1
Acquired in-process research and development and milestones	(26)	(8)
Purchase of product rights and asset acquisition, net of cash acquired	(73)	0
Net Cash Flows Used in Investing Activities	(217)	(179)
Cash Flows from Financing Activities
Proceeds from debt	1,036	80
Repayments of debt	(1,045)	(336)
Payment of long-term debt issuance costs	(36)	0
Employee withholding taxes related to stock-based awards	(18)	(15)
Dividend payments	(223)	(221)
Net Cash Flows Used in Financing Activities	(286)	(492)
Effect of Exchange Rate Changes on Cash and Cash Equivalents	24	(23)
Net Increase (Decrease) in Cash and Cash Equivalents	70	(292)
Cash and Cash Equivalents, Beginning of Period	693	706
Cash and Cash Equivalents, End of Period	$ 763	$ 414

Background and Nature of Operat

Background and Nature of Operations	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background and Nature of Operations	Background and Nature of Operations Organon & Co. (“Organon” or the “Company”) is an independent global healthcare company with a focus on improving the health of women throughout their lives. Organon develops and delivers innovative health solutions through a portfolio of prescription therapies and medical devices within women’s health, biosimilars and established brands (the “Organon Products”). Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. The Company sells these products through various channels including drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. The Company operates six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom. Unless otherwise indicated, trademarks appearing in italics throughout this document are trademarks of, or are used under license by, the Organon group of companies. The Company’s operations include the following product portfolios: • Women’s Health : Organon’s women’s health products are sold by prescription primarily in two therapeutic areas, contraception, with key brands such as Nexplanon® (etonogestrel implant) (sold as Implanon NXT ™ in some countries outside the United States) and NuvaRing® (etonogestrel / ethinyl estradiol vaginal ring), and fertility, with key brands such as Follistim AQ® (follitropin beta injection) (marketed in most countries outside the United States as Puregon ™). Nexplanon is a long-acting reversible contraceptive, which is a class of contraceptives that is recognized as one of the most effective types of hormonal contraception available to patients with a low long-term average cost. Other women’s health products include the Jada ® System, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted, and a license from Daré Biosciences for the global commercial rights to Xaciato ® (clindamycin phosphate vaginal gel, 2%), an FDA-approved medication for the treatment of bacterial vaginosis (“BV”) in females 12 years of age and older. In October 2023, Xaciato was launched in the United States. • Biosimilars : Organon’s current portfolio spans across immunology and oncology treatments. Organon’s oncology biosimilars, Ontruzant® (trastuzumab-dttb) and Aybintio TM 1 (bevacizumab), have been launched in more than 20 countries, Organon’s immunology biosimilars, Brenzys TM 1 (etanercept), Renflexi s ® (infliximab-abda) and Hadlima® (adalimumab-bwwd), have been launched in five countries. All five biosimilars in Organon’s portfolio have launched in Canada, and three biosimilars, Ontruzant , Renflexis and Hadlima have launched in the United States. • Established Brands : Organon has a portfolio of established brands, which generally are beyond market exclusivity, including leading brands in cardiovascular, respiratory, dermatology and non-opioid pain management. A number of Organon’s established brands lost exclusivity years ago and have faced generic competition for some time.

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and disclosures required by GAAP for complete consolidated financial statements are not included herein. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. All intercompany transactions and accounts within Organon have been eliminated. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Organon’s Annual Report on Form 10-K for the year ended December 31, 2023. Use of Estimates The presentation of these Condensed Consolidated Financial Statements and accompanying notes in conformity with GAAP require management to make estimates and assumptions that affect the amounts reported, as further described in the Annual Report on Form 10-K for the year ended December 31, 2023. Accordingly, actual results could differ materially from management’s estimates and assumptions. Recently Issued Accounting Standards Not Yet Adopted In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-09, Improvements to Income Tax Disclosures , which requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. The amendments in this ASU are effective for annual periods beginning on January 1, 2025, and should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. This ASU will have no impact on the Company’s consolidated financial condition or results of operations. The Company is currently evaluating the impact to its income tax disclosures. In November 2023, the FASB issued ASU No. 2023-07, Improvements to Reportable Segment Disclosure s, which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment, and contain other disclosure requirements. The purpose of the amendments is to enable investors to better understand an entity’s overall performance and assess potential future cash flows. The amendments in this ASU are effective for annual periods beginning on January 1, 2024 and interim periods beginning on January 1, 2025, and should be applied on a retrospective basis for all periods presented. This ASU will have no impact on the Company’s consolidated financial condition or results of operations. The Company is currently evaluating the impact to its segment disclosures. Recent Securities and Exchange Commission (“SEC”) Final Rules Not Yet Adopted In March 2024, the SEC adopted final rules under SEC Release No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors , which requires registrants to provide certain climate-related information in their registration statements and annual reports. The rules require information about a registrant's climate-related risks that are reasonably likely to have a material impact on its business, results of operations, or financial condition. The required information about climate-related risks will also include disclosure of a registrant's greenhouse gas emissions. In addition, the rules will require registrants to present certain climate-related financial metrics in their audited financial statements. These requirements are effective for the Company in various fiscal years, starting with its fiscal year beginning January 1, 2025. However, the climate rule is currently stayed which could potentially impact the effective date. Disclosures will be required prospectively, with information for prior periods required only to the extent it was previously disclosed in an SEC filing. The Company is currently evaluating the impact of these final rules on its consolidated financial statements and disclosures.

Acquisitions and Licensing Arra

Acquisitions and Licensing Arrangements	9 Months Ended
	Sep. 30, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Acquisitions and Licensing Arrangements	Acquisitions and Licensing Arrangements Suzhou Centergene Pharmaceuticals (“Centergene”) In September 2024, Organon entered into license and supply agreements with Centergene acquiring the exclusive commercialization rights to its investigational asset, SJ02, a long-acting recombinant human follicle-stimulating hormone carboxyl-terminal peptide fusion protein (FSH-CTP) designed for controlled ovarian stimulation (COS) in combination with a gonadotropin-releasing hormone (GnRH) antagonist to facilitate the development of multiple follicles in women undergoing assisted reproductive technology (ART) programs. Under the terms of the agreement, Organon will pay $12 million of which $6 million will be paid in the fourth quarter of 2024 and $6 million is payable upon Organon obtaining the manufacturing license, which are refundable if the regulatory approval is not obtained or marketing authorization cannot be transferred, and additional regulatory and sales-based milestones of up to $170 million. Organon will recognize regulatory and sales-based milestones when the achievement is probable. Eli Lilly (“Lilly”) In December 2023, Organon announced an agreement with Lilly to become the sole distributor and promoter of the migraine medicines Emgality ® (galcanezumab) and Rayvow ™ (lasmiditan) in Europe. Lilly will remain the marketing authorization holder and will manufacture the products for sale. Under the terms of the agreement, Organon paid an upfront payment of $50 million upon closing of the transaction in January 2024, and recognized sales-based milestones when the achievement was deemed probable. In the first quarter of 2024, the Company recognized an intangible asset of $220 million, comprised of the $50 million upfront payment and $170 million of sales-based milestones that were deemed probable. The intangible asset will be amortized over 10 years. In August of 2024, Organon expanded its agreement with Lilly to become the sole distributor and promoter for Emgality in the following additional markets: Canada, Colombia, Israel, South Korea, Kuwait, Mexico, Qatar, Saudi Arabia, Taiwan, Turkey and the United Arab Emirates. Organon paid an upfront payment of $23 million for the expansion of territory upon closing of the transaction in August 2024, and recognize sales-based milestones when the achievement is probable. As of September 30, 2024, Organon recognized an additional intangible asset of $113 million, comprised of the $23 million upfront payment and $90 million related to the sales-based milestones that were deemed probable. The intangible asset will be amortized over 10 years. As of September 30, 2024, Organon had accrued $20 million in Accrued and Other current liabilities and $240 million in Other noncurrent liabilities in total related to the probable sales-based milestones. Shanghai Henlius Biotech, Inc. (“Henlius”) For the three and nine months ended September 30, 2024 research and development milestones related to the Henlius agreement were determined to be probable of being achieved and the Company expensed $50 million and $70 million, respectively, in Acquired in-process research and development and milestones expense related to the development of HLX11, an investigational biosimilar of Perjeta ® (pertuzumab), and HLX14, an investigational biosimilar of Prolia 2 and Xgeva 2 (denosumab). As of September 30, 2024, $15 million of the Acquired in-process research and development and milestones has been paid. On May 24, 2024, the European Medicines Agency validated the marketing authorization applications for HLX14. On October 30, 2024, the U.S. Food and Drug Administration accepted the biologic license application for HLX14. Cirqle Biomedical (“Cirqle”) For the nine months ended September 30, 2024, research and development milestones related to the Cirqle agreement were determined to be probable of being achieved and the Company expensed and paid $10 million in Acquired in-process research and development and milestones expense.

Earnings per Share (_EPS_)

Earnings per Share (“EPS”)	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Earnings per Share (“EPS”)	Earnings per Share (“EPS”) The calculations of basic and diluted EPS are as follows: Three Months Ended Nine Months Ended ($ in millions and shares in thousands, except per share amounts) 2024 2023 2024 2023 Net income $ 359 $ 58 $ 755 $ 477 Basic weighted average number of shares outstanding 257,498 255,588 256,830 255,112 Stock awards and equity units (share equivalent) 2,259 761 2,078 1,050 Diluted weighted average common shares outstanding 259,757 256,349 258,908 256,162 EPS: Basic $ 1.39 $ 0.23 $ 2.94 $ 1.87 Diluted $ 1.38 $ 0.23 $ 2.92 $ 1.86 Anti-dilutive shares excluded from the calculation of EPS 8,599 10,390 8,587 9,833

Product and Geographic Informat

Product and Geographic Information	9 Months Ended
	Sep. 30, 2024
Segment Reporting [Abstract]
Product and Geographic Information	Product and Geographic Information The Company’s operations include the following product portfolios, which constitute one operating segment engaged in developing and delivering innovative health solutions through its portfolio of prescription therapies and medical devices within women’s health, biosimilars and established brands. Revenues of the Company’s products were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 ($ in millions) U.S. Int’l Total U.S. Int’l Total U.S. Int’l Total U.S. Int’l Total Women’s Health Nexplanon/Implanon NXT $ 172 $ 70 $ 243 $ 146 $ 74 $ 220 $ 497 $ 207 $ 704 $ 418 $ 181 $ 599 Follistim AQ 26 37 63 22 32 54 59 113 171 74 105 179 NuvaRing (1) 7 17 23 23 20 43 33 57 90 70 67 137 Ganirelix Acetate Injection 5 20 26 4 21 25 16 65 82 15 74 88 Marvelon/Mercilon — 29 29 — 30 30 — 103 103 — 97 97 Jada 15 — 16 12 — 13 42 1 43 30 — 31 Other Women’s Health ( 1) (2) 14 28 40 11 22 33 41 78 119 32 74 106 Biosimilars Renflexis 56 16 72 57 12 69 167 43 210 172 29 201 Ontruzant 5 15 20 11 28 40 23 84 107 36 57 93 Brenzys — 27 27 — 13 13 — 63 63 — 45 45 Aybintio — 7 7 — 12 12 — 22 22 — 34 34 Hadlima 29 11 40 2 6 8 71 27 98 2 18 20 Established Brands Cardiovascular Zetia (1) 2 80 81 2 68 69 5 235 240 5 248 253 Vytorin 1 25 26 2 31 33 4 78 82 5 95 100 Atozet — 125 125 — 126 126 — 396 396 — 397 397 Rosuzet — 11 11 — 17 17 — 36 36 — 52 52 Cozaar/Hyzaar 2 57 59 3 65 68 7 179 186 8 217 225 Other Cardiovascular (1) (2) — 27 29 1 39 41 2 97 99 2 110 112 Respiratory Singulair 2 83 85 3 88 91 7 268 275 8 282 290 Nasonex (1) — 63 63 — 60 60 — 200 200 — 197 197 Dulera 38 10 48 40 9 49 120 31 151 116 28 144 Clarinex 1 26 27 2 26 28 2 97 100 4 103 107 Other Respiratory (1) (2) 11 3 14 17 3 20 26 10 35 42 10 52 Non-Opioid Pain, Bone and Dermatology Arcoxia — 69 69 — 64 64 — 211 211 — 207 207 Fosamax 1 37 38 1 40 41 3 109 112 2 121 123 Diprospan — 37 37 — 31 31 — 102 102 — 58 58 Other Non-Opioid Pain, Bone and Dermatology (2) 5 69 74 4 70 74 15 212 227 11 196 207 Other Emgality/Rayvow — 29 29 — — — — 69 69 — — — Proscar — 23 23 — 25 25 1 72 73 1 76 77 Propecia 2 27 28 2 21 22 5 74 79 5 86 92 Other (2) 3 80 84 5 72 76 12 229 241 10 231 240 Other (3) 1 26 26 — 24 24 (2) 87 85 (1) 103 102 Revenues $ 398 $ 1,184 $ 1,582 $ 370 $ 1,149 $ 1,519 $ 1,156 $ 3,655 $ 4,811 $ 1,067 $ 3,598 $ 4,665 Totals may not foot due to rounding. Trademarks appearing above in italics are trademarks of, or are used under license by, the Organon group of companies. (1) Sales of the authorized generic versions of NuvaRing, Zetia and Nasonex were previously included in other and have been reclassified to their respective brand name product. (2) Includes sales of products not listed separately. (3) Includes manufacturing sales to third parties. Revenues by geographic area where derived are as follows: Three Months Ended Nine Months Ended ($ in millions) 2024 2023 2024 2023 Europe and Canada $ 436 $ 392 $ 1,343 $ 1,259 United States 398 370 1,156 1,067 Asia Pacific and Japan 260 284 806 869 China 212 202 634 661 Latin America, Middle East, Russia, and Africa 243 239 768 687 Other (1) 33 32 104 122 Revenues $ 1,582 $ 1,519 $ 4,811 $ 4,665 (1) Primarily reflects manufacturing sales to third parties.

Stock-Based Compensation Plans

Stock-Based Compensation Plans	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation Plans	Stock-Based Compensation Plans The Company grants stock option awards, performance share units (“PSUs”) and restricted share units (“RSUs”) pursuant to its 2021 Incentive Stock Plan. The PSU awards are based on the following performance factors: • total stockholder return of the Company relative to an index of peer companies specified in the awards; and • the results of cumulative free cash flow and revenue metrics of the Company. PSUs include awards issued where the service inception date precedes the grant date. The grant date for the performance conditions is the date grantees have a mutual understanding of the key terms and conditions of the award, which will occur when the performance condition is objectively determinable and measurable. Recognition of stock-based compensation occurs at the service inception date. Measurement of stock-based compensation attributed to the PSUs will be based on the fair value of the underlying common stock once the grant date is determined. Stock-based compensation expenses incurred by the Company were as follows: Three Months Ended Nine Months Ended ($ in millions) 2024 2023 2024 2023 Stock-based compensation expense recognized in: Cost of sales $ 4 $ 5 $ 13 $ 13 Selling, general and administrative 17 18 53 50 Research and development 4 4 13 11 Total $ 25 $ 27 $ 79 $ 74 Income tax benefits $ 6 $ 6 $ 17 $ 16 The fair value of options granted was determined using the following assumptions: Nine Months Ended September 30, 2024 2023 Expected dividend yield 6.00 % 4.82 % Risk-free interest rate 4.12 3.56 Expected volatility 41.02 42.30 Expected life (years) 5.89 5.89 A summary of the equity award transactions for the nine months ended September 30, 2024 is as follows: Stock Options RSUs PSUs (shares in thousands) Shares Weighted average exercise price Weighted average grant date fair value Shares Weighted average grant date fair value Shares Weighted average grant date fair value Outstanding as of January 1, 2024 5,758 $ 32.20 $ 8.51 7,511 $ 25.05 1,122 $ 30.16 Granted/Issued 1,503 18.80 4.59 4,695 18.81 184 31.25 Vested/Exercised — — — (2,952) 29.47 (56) 51.63 Forfeited/Cancelled (314) 29.11 7.66 (864) 21.73 (129) 37.44 Outstanding as of September 30, 2024 6,947 $ 29.44 $ 7.70 8,390 $ 20.34 1,121 $ 28.44 The following table summarizes information about equity awards outstanding that are vested and expected to vest and equity awards outstanding that are exercisable as of September 30, 2024: Equity Awards Vested and Expected to Vest Equity Awards That are Exercisable (awards in thousands; aggregate intrinsic value in millions) Awards Weighted Average Exercise Price Aggregate Intrinsic Value Remaining Term (in years) Awards Weighted Average Exercise Price Aggregate Intrinsic Value Remaining Term (in years) Stock Options 6,772 $ 29.45 $ — 6.83 4,658 $ 33.55 $ — 5.72 RSUs 7,791 160 1.97 PSUs 854 18 1.54 The amount of unrecognized compensation costs as of September 30, 2024 was $160 million, which will be recognized in operating expense ratably over the weighted average vesting period of 1.95 years.

Restructuring

Restructuring	9 Months Ended
	Sep. 30, 2024
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring In the first quarter of 2024, Organon implemented additional restructuring activities related to the ongoing optimization of its internal operations by reducing headcount, primarily in the research and development function. In the fourth quarter of 2023, Organon implemented restructuring activities related to the ongoing optimization of its internal operations by reducing headcount in certain markets and functions. As a result of these combined activities, the Company’s headcount will be reduced by approximately 5% by the end of 2024. Organon expects the remaining severance payments associated with the restructuring activities to be paid by the end of 2024. The following is a summary of changes in severance liabilities related to the restructuring activities included within Accrued and other current liabilities : September 30, 2024 December 31, 2023 Beginning balance $ 61 $ 20 Severance & severance related costs 23 62 Cash payments and other (60) (21) Ending Balance $ 24 $ 61

Taxes on Income

Taxes on Income	9 Months Ended
	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Taxes on Income	Taxes on Income The effective income tax rates were (73.7)% and 27.0% for the three months ended September 30, 2024 and 2023, respectively, and (11.3)% and 16.1% for the nine months ended September 30, 2024 and 2023, respectively. These effective income tax rates reflect the beneficial impact of foreign earnings, offset by the impact of U.S. inclusions under the Global Intangible Low-Taxed Income regime and a partial valuation allowance recorded against non-deductible U.S. interest expense. There was a favorable impact to the 2024 year-to-date effective tax rate, which was driven by the favorable closure of the two non-US tax audits and a return to provision adjustment for the Switzerland entity. In the third quarter of 2024, the Swiss tax authority confirmed to the Company the applicable useful life of an existing tax asset. As a result, the Company has now concluded it is more likely than not it will utilize the entirety of the tax asset. As such, the Company released a $210 million related valuation allowance.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2024
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consisted of: ($ in millions) September 30, 2024 December 31, 2023 Finished goods $ 719 $ 566 Raw materials 26 110 Work in process 697 684 Supplies 77 65 Total (approximates current cost) $ 1,519 $ 1,425 Decrease to last in, first out (“LIFO”) costs (6) — $ 1,513 $ 1,425 Recognized as: Inventories $ 1,383 $ 1,315 Other assets 130 110 Inventories valued under the LIFO method 160 105 Amounts recognized as Other assets

Long-Term Debt

Long-Term Debt	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Long-Term Debt	Long-Term Debt The following is a summary of Organon’s total debt: ($ in millions) September 30, 2024 December 31, 2023 Term Loan B Facility: SOFR plus 250 bps term loan due 2031 (1) $ 1,543 $ 2,543 EURIBOR plus 300 bps euro-denominated term loan due 2028 (€726 million in 2024 and €731 million in 2023) 809 809 4.125% secured notes due 2028 2,100 2,100 2.875% euro-denominated secured notes due 2028 (€1.25 billion) 1,394 1,384 5.125% notes due 2031 2,000 2,000 6.750% secured notes due 2034 500 — 7.875% notes due 2034 500 — Other borrowings 8 8 Other (discounts and debt issuance costs) (105) (84) Total principal long-term debt $ 8,749 $ 8,760 Less: Current portion of long-term debt 10 9 Total Long-term debt, net of current portion $ 8,739 $ 8,751 (1) Prior to entering into Amendment No. 2 to the Senior Secured Credit Agreement on May 17, 2024, the maturity date was 2028. The nature and terms of Organon’s long-term debt are described in detail in Note 16. “Long-Term Debt and Leases” in the 2023 Annual Report on Form 10-K for the year ended December 31, 2023. During the second quarter of 2024, Organon issued $500 million of 6.750% senior secured notes due 2034 (the “2034 Secured Notes”) and $500 million of 7.875% senior unsecured notes due 2034 (the “2034 Unsecured Notes” and, together with the Secured Notes the “2034 Notes”). Each series of notes is guaranteed by each of the entities that guarantees the Companies’ existing senior secured credit facilities (the “Credit Facilities”). Organon used the net proceeds from the sale of the 2034 Notes to repay a portion of its borrowings under the Credit Facilities’ U.S. dollar-denominated “tranche B” term loan and to pay the fees and expenses incurred in connection with the foregoing. On May 17, 2024, Organon entered into Amendment No. 2 to the Senior Secured Credit Agreement (“Amendment No. 2”) which, among other things, (i) extended the maturity of the U.S. Dollar Term Loan B Facility to May 17, 2031, (ii) extended the maturity of the revolving credit loans made under the senior secured credit facility (the “Revolving Facility”) to December 2, 2027, (iii) increased the maximum amount of the Revolving Facility by $300 million and decreased the commitment fee payable in respect of the Revolving Facility to 0.375%, (iv) removed the credit spread adjustment applicable to SOFR loans, and (v) reduced the interest rate in respect of the remaining $1.55 billion of loans under the U.S. Dollar Term Loan B Facility from Term SOFR plus 3.0% to Term SOFR plus 2.50%. During the second quarter of 2024, the Company borrowed $36 million on the Revolving Facility and subsequently repaid the amount on June 17, 2024. As of September 30, 2024 there were no outstanding balances under the Revolving Facility. In October 2024, the Company borrowed $100 million on the Revolving Facility. During the second quarter of 2024, the Company recorded approximately $36 million of deferred debt issuance costs and discounts related to the 2034 Notes and Amendment No. 2. Debt issuance costs and discounts are presented as a reduction of debt on the Condensed Consolidated Balance Sheets and are amortized as a component of interest expense over the term on the related debt using the effective interest method. Long-term debt was recorded at the carrying amount. The estimated fair value of long-term debt (including current portion) is as follows: ($ in millions) September 30, 2024 December 31, 2023 Long-term debt $ 8,642 $ 8,253 Fair value was estimated using inputs other than quoted prices in active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability and would be considered Level 2 in the fair value hierarchy. The Company made interest payments related to its debt instruments of $292 million for the nine months ended September 30, 2024. The average maturity of the Company’s long-term debt as of September 30, 2024 is approximately 5.5 years and the weighted-average interest rate on total borrowings as of September 30, 2024 is 5.3%. On June 26, 2024, the Company made a discretionary prepayment of $7.5 million on the U.S. Dollar-denominated term loan. The schedule of principal payments required on long-term debt for the next five years and thereafter is as follows: ($ in millions) 2024 $ 2 2025 9 2026 10 2027 9 2028 4,277 Thereafter 4,547 The Senior Credit Agreement contains customary financial covenants, including a total leverage ratio covenant, which measures the ratio of (i) consolidated total debt to (ii) consolidated earnings before interest, taxes, depreciation and amortization, and subject to other adjustments, that must meet certain defined limits which are tested on a quarterly basis. In addition, the Senior Credit Agreement contains covenants that limit, among other things, Organon’s ability to prepay, redeem or repurchase its subordinated and junior lien debt, incur additional debt, make acquisitions, merge with other entities, pay dividends or distributions, redeem, or repurchase equity interests, and create or become subject to liens. As of September 30, 2024, the Company is in compliance with all financial covenants and no default or event of default has occurred.

Financial Instruments

Financial Instruments	9 Months Ended
	Sep. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments	Financial Instruments Foreign Currency Risk Management The Company uses a balance sheet risk management program to partially mitigate the exposure of net monetary assets of its subsidiaries that are denominated in a currency other than a subsidiary’s functional currency from the effects of volatility in foreign exchange. In these instances, Organon principally utilizes forward exchange contracts to partially offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro, Swiss franc, and Japanese yen. For exposures in developing country currencies, the Company enters into forward contracts to partially offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. Forward Contracts Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in Exchange losses in the Condensed Consolidated Statements of Income . The forward contracts are not designated as hedges and are marked to market through Exchange losses in the Condensed Consolidated Statements of Income . Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than one year. The notional amount of forward contracts was $1.5 billion and $1.4 billion as of September 30, 2024 and December 31, 2023, respectively. The cash flows and the related gains and losses from these contracts are reported as operating activities in the Condensed Consolidated Statements of Cash Flows. Net Investment Hedge Euro-denominated debt instruments Foreign exchange risk is also managed through the use of economic hedges on foreign currency balances. €726 million of the euro-denominated term loan and €1.25 billion of the 2.875% euro-denominated secured notes have been designated and are effective as a hedge of the net investment in euro-denominated subsidiaries. See Note 10 “Long-Term Debt” for additional details. Cross-Currency Swaps In conjunction with the issuance of the 2034 Notes, the Company entered into cross-currency swaps that mature in 2029. The Company elected to designate the fixed-for-fixed swaps as a hedge of the net investment in euro-denominated subsidiaries balance and the change in the fair value attributable to the changes in the spot rate will be recorded in Other Comprehensive Income (Loss), Net of Taxes. Throughout the term of the swaps, the Company will pay a fixed interest rate of 5.8330% based on the Euro notional amount of €922 million and receive a fixed interest rate of 7.3125% based on the U.S. dollar notional amount of $1 billion. The notional amount based on the Euro leg of the cross-currency swaps has been designated and is effective as a hedge of the net investment in euro-denominated subsidiaries. The difference between the interest rate received and paid under the cross-currency swap agreements is recorded in Interest expense in the Condensed Consolidated Statements of Income. The cash flows and the related gains and losses from the periodic settlements of the cross-currency swaps are reported as Operating Activities in the Condensed Consolidated Statements of Cash Flows. The Company measures fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions. The following financial instruments were recorded at their estimated fair value. The recurring fair value measurement of the assets and liabilities was as follows: ($ in millions) Fair Value Measurement Level September 30, 2024 December 31, 2023 Forward contracts in Other current assets 2 $ 10 $ 9 Forward contracts in Accrued and other current liabilities 2 27 16 Cross-currency swap in Other noncurrent liabilities 2 25 — Foreign currency gain (loss) due to spot rate fluctuations on the euro-denominated debt instruments and the change in fair value of the cross-currency swaps resulting from hedge designation were included within Cumulative translation adjustment in Other comprehensive income (loss): Three Months Ended Nine Months Ended ($ in millions) 2024 2023 2024 2023 Euro-denominated debt instruments (loss) gain $ (92) $ 79 $ (17) $ 21 Cross-currency swaps loss (29) — (25) — The Condensed Consolidated Statements of Income include the impact of net (gains) losses of Organon’s derivative financial instruments: Three Months Ended Nine Months Ended ($ in millions) 2024 2023 2024 2023 Derivative loss (gain) in Exchange losses $ 14 $ (12) $ 5 $ (25) Derivative gain in Interest expense (3) — (5) — Concentrations of Credit Risk Organon has established accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. Under these agreements, Organon factored $39 million and $66 million of accounts receivable as of September 30, 2024 and December 31, 2023, respectively, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within Operating Activities in the Condensed Consolidated Statements of Cash Flows.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss) Changes in Accumulated other comprehensive income (loss) by component are as follows: ($ in millions) Employee Cumulative Accumulated Other Comprehensive (Loss) Income Balance at July 1, 2023, net of taxes $ 9 $ (542) $ (533) Other comprehensive loss, pretax — (43) (43) Tax — — — Other comprehensive loss, net of taxes — (43) (43) Balance at September 30, 2023, net of taxes $ 9 $ (585) $ (576) Balance at July 1, 2024, net of taxes $ (14) $ (598) $ (612) Other comprehensive (loss) income, pretax (1) 42 41 Tax — — — Other comprehensive (loss) income, net of taxes (1) 42 41 Balance at September 30, 2024, net of taxes $ (15) $ (556) $ (571) Balance at January 1, 2023, net of taxes $ 10 $ (574) $ (564) Other comprehensive loss, pretax (1) (11) (12) Tax — — — Other comprehensive loss, net of taxes (1) (11) (12) Balance at September 30, 2023, net of taxes $ 9 $ (585) $ (576) Balance at January 1, 2024, net of taxes $ (15) $ (526) $ (541) Other comprehensive loss, pretax — (30) (30) Tax — — — Other comprehensive loss, net of taxes — (30) (30) Balance at September 30, 2024, net of taxes $ (15) $ (556) $ (571)

Samsung Collaboration

Samsung Collaboration	9 Months Ended
	Sep. 30, 2024
Revenue from Contract with Customer [Abstract]
Samsung Collaboration	Samsung Collaboration The Company has an agreement with Samsung Bioepis Co., Ltd. (“Samsung Bioepis”) to develop and commercialize multiple pre-specified biosimilar candidates, which have since launched and are part of the Company's product portfolio. Under the agreement, Samsung Bioepis is responsible for preclinical and clinical development, process development and manufacturing, clinical trials and registration of product candidates, and the Company has an exclusive license for worldwide commercialization with certain geographic exceptions specified on a product-by-product basis. The Company's access rights to each product under the agreement last for 10 years from each product's launch date on a market-by-market basis. Gross profits are shared equally in all markets with the exception of certain markets in Brazil where gross profits are shared 65% to Samsung Bioepis and 35% to the Company. Since the Company is the principal on sales transactions with third parties, the Company recognizes sales, cost of sales and selling, general and administrative expenses on a gross basis. Generally, profit sharing adjustments are recorded either to Cost of sales (after commercialization) or Selling, general and administrative expenses (prior to commercialization). Samsung Bioepis is eligible for additional payments associated with pre-specified clinical and regulatory milestones. As of September 30, 2024, potential future regulatory milestone payments of $25 million remain under the agreement. Summarized information related to this collaboration is as follows: Three Months Ended Nine Months Ended ($ in millions) 2024 2023 2024 2023 Sales $ 164 $ 143 $ 499 $ 394 Cost of sales 112 98 329 272 Selling, general and administrative 18 17 60 53 ($ in millions) September 30, 2024 December 31, 2023 Receivables from Samsung included in Other current assets $ 44 $ — Payables to Samsung included in Trade accounts payable 99 104

Third-Party Arrangements

Third-Party Arrangements	9 Months Ended
	Sep. 30, 2024
Related Party Transactions [Abstract]
Third-Party Arrangements	Third-Party Arrangements On June 2, 2021, Organon and Merck & Co., Inc. (“Merck”) entered into a Separation and Distribution Agreement (the “Separation and Distribution Agreement”). Pursuant to the Separation and Distribution Agreement, Merck agreed to spin off the Organon Products into Organon, a new, publicly-traded company (the “Separation”). The Separation was completed pursuant to the Separation and Distribution Agreement and other agreements with Merck related to the Separation. As of September 30, 2024, only one jurisdiction remains under an Interim Operating Model Agreement. Under the manufacturing and supply agreements, the Company manufactures certain products for Merck, or its applicable affiliate, and Merck manufactures certain products for the Company, or its applicable affiliate. For details on the rights and responsibilities of the parties under the agreements, refer to Note 19 “Third-Party Arrangements and Related Party Disclosures” to the audited Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. The amounts due under such agreements were: ($ in millions) September 30, 2024 December 31, 2023 Due from Merck in Accounts receivable $ 207 $ 583 Due to Merck in Accounts payable 434 619 Sales and cost of sales resulting from the manufacturing and supply agreements with Merck were: Three Months Ended Nine Months Ended ($ in millions) 2024 2023 2024 2023 Sales $ 25 $ 28 $ 82 $ 95 Cost of sales 24 25 76 88

Contingencies

Contingencies	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies Organon is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. Organon records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Given the nature of the litigation discussed in this note and the complexities involved in these matters, Organon is unable to reasonably estimate a possible loss or range of possible loss for such matters until Organon knows, among other factors, (i) what claims, if any, will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation, and (v) any other factors that may have a material effect on the litigation. Organon’s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. Organon has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities. Reference is made below to certain litigation in which Merck, but not Organon, is named as a defendant. Pursuant to the Separation and Distribution Agreement, Organon is required to indemnify Merck for liabilities relating to, arising from, or resulting from such litigation. Product Liability Litigation Fosamax Merck is a defendant in product liability lawsuits in the United States involving Fosamax® (alendronate sodium) (the “Fosamax Litigation”). As of September 30, 2024, approximately 3,085 cases comprising the Fosamax Litigation are pending against Merck in either federal or state court. Plaintiffs in the vast majority of these cases generally allege that they sustained femur fractures and/or other bone injuries (“Femur Fractures”) in association with the use of Fosamax . All federal cases involving allegations of Femur Fractures have been or will be transferred to a multidistrict litigation in the District of New Jersey (“Femur Fracture MDL”). In the only bellwether case tried to date in the Femur Fracture MDL, Glynn v. Merck , the jury returned a verdict in Merck’s favor. In addition, in June 2013, the Femur Fracture MDL court granted Merck’s motion for judgment as a matter of law in the Glynn case and held that the plaintiff’s failure to warn claim was preempted by federal law. In August 2013, the Femur Fracture MDL court entered an order requiring plaintiffs in the Femur Fracture MDL to show cause why those cases asserting claims for a femur fracture injury that took place prior to September 14, 2010, should not be dismissed based on the court’s preemption decision in the Glynn case. Pursuant to the show cause order, in March 2014, the Femur Fracture MDL court dismissed with prejudice approximately 650 cases on preemption grounds. Plaintiffs in approximately 515 of those cases appealed that decision to the U.S. Court of Appeals for the Third Circuit (“Third Circuit”). In March 2017, the Third Circuit issued a decision reversing the Femur Fracture MDL court’s preemption ruling and remanding the appealed cases back to the Femur Fracture MDL court. In May 2019, the U.S. Supreme Court decided that the Third Circuit had incorrectly concluded that the issue of preemption should be resolved by a jury, and accordingly vacated the judgment of the Third Circuit and remanded the proceedings back to the Third Circuit to address the issue in a manner consistent with the Supreme Court’s opinion. In November 2019, the Third Circuit remanded the cases back to the District Court in order to allow that court to determine in the first instance whether the plaintiffs’ state law claims are preempted by federal law under the standards described by the Supreme Court in its opinion. On March 23, 2022, the District Court granted Merck’s motion and ruled that plaintiffs’ failure to warn claims are preempted as a matter of law to the extent they assert that Merck should have added a Warning or Precaution regarding atypical femur fractures prior to October 2010. On July 11, 2022, the District Court entered an Order to Show Cause as to why the Court should not dismiss either with prejudice or conditionally all of plaintiffs’ claims that are not dependent on the preempted failure to warn claims. On November 18, 2022, as a result of the Order to Show Cause, the District Court entered a Final Judgment resulting in the dismissal with prejudice of all plaintiffs in the MDL. On December 16, 2022, those plaintiffs filed their Notice of Appeal to the Third Circuit challenging the District Court’s preemption ruling. 974 of the 975 cases previously pending in the Femur Fracture MDL have either been dismissed or are on appeal to the Third Circuit. Plaintiff’s motion to remand one case back to its transferor court is pending. On September 20, 2024, the Third Circuit issued an Opinion finding that plaintiffs’ failure to warn claims were not preempted and remanded all cases back to the District Court for further proceedings. As of September 30, 2024, approximately 1,830 cases alleging Femur Fractures have been filed in New Jersey state court and are pending in Middlesex County. The parties selected an initial group of cases to be reviewed through fact discovery, and Merck continues to select additional cases to be reviewed. As of September 30, 2024, approximately 275 cases alleging Femur Fractures have been filed and are pending in California state court. All of the Femur Fracture cases filed in California state court have been consolidated before a single judge in Orange County, California. Additionally, there are four Femur Fracture cases pending in other state courts. Discovery is presently stayed in the Femur Fracture MDL and in the state court in California. Nexplanon/Implanon Merck is a defendant in lawsuits brought by individuals relating to the use of Nexplanon and Implanon™ (etonogestrel implant). There are two filed product liability actions involving Implanon , both of which are pending in the Northern District of Ohio as well as 56 unfiled cases involving Implanon alleging similar injuries, all of which have been tolled under a written tolling agreement. As of September 30, 2024, Merck had 21 cases pending outside the United States, of which 11 relate to Implanon and 10 relate to Nexplanon . Governmental Proceedings From time to time, Organon’s subsidiaries may receive inquiries and may be the subject of preliminary investigation activities from competition and/or other governmental authorities, including in markets outside the United States. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to Organon, monetary fines and/or remedial undertakings may be required. Subject to certain exceptions specified in the Separation and Distribution Agreement, Organon assumed liability for all pending and threatened legal matters related to products transferred from Merck to Organon in connection with the spinoff, including competition investigations resulting from enforcement activity concerning Merck’s conduct involving Organon’s products. Organon could be obligated to indemnify Merck for fines or penalties, or a portion thereof, resulting from such investigations. Patent Litigation From time to time, generic manufacturers of pharmaceutical products file Abbreviated New Drug Applications with the FDA seeking to market generic forms of Organon’s products prior to the expiration of relevant patents owned by Organon. To protect its patent rights, Organon may file patent infringement lawsuits against such generic companies. Similar lawsuits defending Organon’s patent rights may exist in other countries. Organon intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products, potential payment of damages and legal fees, and, with respect to products acquired through acquisitions, potentially significant intangible asset impairment charges. Nexplanon In June 2017, Microspherix LLC (“Microspherix”) sued Organon in the U.S. District Court for the District of New Jersey asserting that the manufacturing, use, sale and importation of Nexplanon infringed several of Microspherix’s patents that claim radio-opaque, implantable drug delivery devices. Microspherix claimed damages from September 2014 until the patents expired in May 2021. In December 2023, the parties executed a settlement agreement and the district court dismissed the case. Organon made its first payment of $35 million in December 2023, its second payment of $25 million in August 2024, and has reserved $20 million to cover the remainder of the settlement. Other Litigation In addition to the matters described above, there are various other pending legal proceedings involving Organon, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of Organon as of September 30, 2024, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to Organon’s financial condition, results of operations or cash flows either individually or in the aggregate. Legal Defense Reserves Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by Organon; the development of Organon’s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against Organon; and the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The legal defense reserve as of September 30, 2024 and December 31, 2023 was $17 million and $20 million, respectively, and represented Organon’s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by Organon. Organon will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Dermavant Sciences Ltd. (“Dermavant”) On October 28, 2024, Organon acquired Dermavant, a company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology. Dermavant’s novel product, Vtama ® (tapinarof) cream, 1%, for the topical treatment of mild, moderate, and severe plaque psoriasis in adults, was approved by the U.S. Food and Drug Administration (FDA) in May 2022. It is currently being reviewed by the FDA for the treatment of atopic dermatitis, also known as eczema, in adults and children 2 years of age and older. Atopic dermatitis is one of the most common inflammatory dermatological conditions in adults, presenting a higher disease burden for women compared to men. The transaction will be accounted for as an acquisition of a business. Consideration consists of an upfront payment of $175 million and a $75 million milestone payment upon regulatory approval, as well as payments of up to $950 million for the achievements of certain commercial milestones, tiered royalties on net sales, and the assumption of liabilities, including certain debt obligations, which would be accounted for at fair value on the acquisition date. Organon incurred costs associated with the transaction of approximately $4 million recognized in Selling, general and administrative expenses for the three and nine months ended September 30, 2024. Oss Biotech Site

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net income	$ 359	$ 58	$ 755	$ 477

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Basis of Presentation (Policies

Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Accounting	The accompanying unaudited financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and disclosures required by GAAP for complete consolidated financial statements are not included herein. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. All intercompany transactions and accounts within Organon have been eliminated. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Organon’s Annual Report on Form 10-K for the year ended December 31, 2023.
Use of Estimates	Use of Estimates The presentation of these Condensed Consolidated Financial Statements and accompanying notes in conformity with GAAP require management to make estimates and assumptions that affect the amounts reported, as further described in the Annual Report on Form 10-K for the year ended December 31, 2023. Accordingly, actual results could differ materially from management’s estimates and assumptions.
Recently Issued Accounting Standards Not Yet Adopted	Recently Issued Accounting Standards Not Yet Adopted In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-09, Improvements to Income Tax Disclosures , which requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. The amendments in this ASU are effective for annual periods beginning on January 1, 2025, and should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. This ASU will have no impact on the Company’s consolidated financial condition or results of operations. The Company is currently evaluating the impact to its income tax disclosures. In November 2023, the FASB issued ASU No. 2023-07, Improvements to Reportable Segment Disclosure s, which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment, and contain other disclosure requirements. The purpose of the amendments is to enable investors to better understand an entity’s overall performance and assess potential future cash flows. The amendments in this ASU are effective for annual periods beginning on January 1, 2024 and interim periods beginning on January 1, 2025, and should be applied on a retrospective basis for all periods presented. This ASU will have no impact on the Company’s consolidated financial condition or results of operations. The Company is currently evaluating the impact to its segment disclosures. Recent Securities and Exchange Commission (“SEC”) Final Rules Not Yet Adopted In March 2024, the SEC adopted final rules under SEC Release No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors , which requires registrants to provide certain climate-related information in their registration statements and annual reports. The rules require information about a registrant's climate-related risks that are reasonably likely to have a material impact on its business, results of operations, or financial condition. The required information about climate-related risks will also include disclosure of a registrant's greenhouse gas emissions. In addition, the rules will require registrants to present certain climate-related financial metrics in their audited financial statements. These requirements are effective for the Company in various fiscal years, starting with its fiscal year beginning January 1, 2025. However, the climate rule is currently stayed which could potentially impact the effective date. Disclosures will be required prospectively, with information for prior periods required only to the extent it was previously disclosed in an SEC filing. The Company is currently evaluating the impact of these final rules on its consolidated financial statements and disclosures.

Earnings per Share (_EPS_) (Tab

Earnings per Share (“EPS”) (Tables)	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Earnings Per Common Share	The calculations of basic and diluted EPS are as follows: Three Months Ended Nine Months Ended ($ in millions and shares in thousands, except per share amounts) 2024 2023 2024 2023 Net income $ 359 $ 58 $ 755 $ 477 Basic weighted average number of shares outstanding 257,498 255,588 256,830 255,112 Stock awards and equity units (share equivalent) 2,259 761 2,078 1,050 Diluted weighted average common shares outstanding 259,757 256,349 258,908 256,162 EPS: Basic $ 1.39 $ 0.23 $ 2.94 $ 1.87 Diluted $ 1.38 $ 0.23 $ 2.92 $ 1.86 Anti-dilutive shares excluded from the calculation of EPS 8,599 10,390 8,587 9,833

Product and Geographic Inform_2

Product and Geographic Information (Tables)	9 Months Ended
	Sep. 30, 2024
Segment Reporting [Abstract]
Schedule of Sales of Company's Products	Revenues of the Company’s products were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 ($ in millions) U.S. Int’l Total U.S. Int’l Total U.S. Int’l Total U.S. Int’l Total Women’s Health Nexplanon/Implanon NXT $ 172 $ 70 $ 243 $ 146 $ 74 $ 220 $ 497 $ 207 $ 704 $ 418 $ 181 $ 599 Follistim AQ 26 37 63 22 32 54 59 113 171 74 105 179 NuvaRing (1) 7 17 23 23 20 43 33 57 90 70 67 137 Ganirelix Acetate Injection 5 20 26 4 21 25 16 65 82 15 74 88 Marvelon/Mercilon — 29 29 — 30 30 — 103 103 — 97 97 Jada 15 — 16 12 — 13 42 1 43 30 — 31 Other Women’s Health ( 1) (2) 14 28 40 11 22 33 41 78 119 32 74 106 Biosimilars Renflexis 56 16 72 57 12 69 167 43 210 172 29 201 Ontruzant 5 15 20 11 28 40 23 84 107 36 57 93 Brenzys — 27 27 — 13 13 — 63 63 — 45 45 Aybintio — 7 7 — 12 12 — 22 22 — 34 34 Hadlima 29 11 40 2 6 8 71 27 98 2 18 20 Established Brands Cardiovascular Zetia (1) 2 80 81 2 68 69 5 235 240 5 248 253 Vytorin 1 25 26 2 31 33 4 78 82 5 95 100 Atozet — 125 125 — 126 126 — 396 396 — 397 397 Rosuzet — 11 11 — 17 17 — 36 36 — 52 52 Cozaar/Hyzaar 2 57 59 3 65 68 7 179 186 8 217 225 Other Cardiovascular (1) (2) — 27 29 1 39 41 2 97 99 2 110 112 Respiratory Singulair 2 83 85 3 88 91 7 268 275 8 282 290 Nasonex (1) — 63 63 — 60 60 — 200 200 — 197 197 Dulera 38 10 48 40 9 49 120 31 151 116 28 144 Clarinex 1 26 27 2 26 28 2 97 100 4 103 107 Other Respiratory (1) (2) 11 3 14 17 3 20 26 10 35 42 10 52 Non-Opioid Pain, Bone and Dermatology Arcoxia — 69 69 — 64 64 — 211 211 — 207 207 Fosamax 1 37 38 1 40 41 3 109 112 2 121 123 Diprospan — 37 37 — 31 31 — 102 102 — 58 58 Other Non-Opioid Pain, Bone and Dermatology (2) 5 69 74 4 70 74 15 212 227 11 196 207 Other Emgality/Rayvow — 29 29 — — — — 69 69 — — — Proscar — 23 23 — 25 25 1 72 73 1 76 77 Propecia 2 27 28 2 21 22 5 74 79 5 86 92 Other (2) 3 80 84 5 72 76 12 229 241 10 231 240 Other (3) 1 26 26 — 24 24 (2) 87 85 (1) 103 102 Revenues $ 398 $ 1,184 $ 1,582 $ 370 $ 1,149 $ 1,519 $ 1,156 $ 3,655 $ 4,811 $ 1,067 $ 3,598 $ 4,665 Totals may not foot due to rounding. Trademarks appearing above in italics are trademarks of, or are used under license by, the Organon group of companies. (1) Sales of the authorized generic versions of NuvaRing, Zetia and Nasonex were previously included in other and have been reclassified to their respective brand name product. (2) Includes sales of products not listed separately. (3) Includes manufacturing sales to third parties.
Schedule of Consolidated Revenues by Geographic Area	Revenues by geographic area where derived are as follows: Three Months Ended Nine Months Ended ($ in millions) 2024 2023 2024 2023 Europe and Canada $ 436 $ 392 $ 1,343 $ 1,259 United States 398 370 1,156 1,067 Asia Pacific and Japan 260 284 806 869 China 212 202 634 661 Latin America, Middle East, Russia, and Africa 243 239 768 687 Other (1) 33 32 104 122 Revenues $ 1,582 $ 1,519 $ 4,811 $ 4,665 (1) Primarily reflects manufacturing sales to third parties.

Stock-Based Compensation Plans

Stock-Based Compensation Plans (Tables)	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Stock-based Compensation Expenses	Stock-based compensation expenses incurred by the Company were as follows: Three Months Ended Nine Months Ended ($ in millions) 2024 2023 2024 2023 Stock-based compensation expense recognized in: Cost of sales $ 4 $ 5 $ 13 $ 13 Selling, general and administrative 17 18 53 50 Research and development 4 4 13 11 Total $ 25 $ 27 $ 79 $ 74 Income tax benefits $ 6 $ 6 $ 17 $ 16
Schedule of Stock Option Valuation Assumptions	The fair value of options granted was determined using the following assumptions: Nine Months Ended September 30, 2024 2023 Expected dividend yield 6.00 % 4.82 % Risk-free interest rate 4.12 3.56 Expected volatility 41.02 42.30 Expected life (years) 5.89 5.89
Schedule of Equity Award Transactions	A summary of the equity award transactions for the nine months ended September 30, 2024 is as follows: Stock Options RSUs PSUs (shares in thousands) Shares Weighted average exercise price Weighted average grant date fair value Shares Weighted average grant date fair value Shares Weighted average grant date fair value Outstanding as of January 1, 2024 5,758 $ 32.20 $ 8.51 7,511 $ 25.05 1,122 $ 30.16 Granted/Issued 1,503 18.80 4.59 4,695 18.81 184 31.25 Vested/Exercised — — — (2,952) 29.47 (56) 51.63 Forfeited/Cancelled (314) 29.11 7.66 (864) 21.73 (129) 37.44 Outstanding as of September 30, 2024 6,947 $ 29.44 $ 7.70 8,390 $ 20.34 1,121 $ 28.44
Schedule of Equity Awards Outstanding	The following table summarizes information about equity awards outstanding that are vested and expected to vest and equity awards outstanding that are exercisable as of September 30, 2024: Equity Awards Vested and Expected to Vest Equity Awards That are Exercisable (awards in thousands; aggregate intrinsic value in millions) Awards Weighted Average Exercise Price Aggregate Intrinsic Value Remaining Term (in years) Awards Weighted Average Exercise Price Aggregate Intrinsic Value Remaining Term (in years) Stock Options 6,772 $ 29.45 $ — 6.83 4,658 $ 33.55 $ — 5.72 RSUs 7,791 160 1.97 PSUs 854 18 1.54

Restructuring (Tables)

Restructuring (Tables)	9 Months Ended
	Sep. 30, 2024
Restructuring and Related Activities [Abstract]
Schedule of Accrued and Other Current Liabilities	The following is a summary of changes in severance liabilities related to the restructuring activities included within Accrued and other current liabilities : September 30, 2024 December 31, 2023 Beginning balance $ 61 $ 20 Severance & severance related costs 23 62 Cash payments and other (60) (21) Ending Balance $ 24 $ 61

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2024
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories consisted of: ($ in millions) September 30, 2024 December 31, 2023 Finished goods $ 719 $ 566 Raw materials 26 110 Work in process 697 684 Supplies 77 65 Total (approximates current cost) $ 1,519 $ 1,425 Decrease to last in, first out (“LIFO”) costs (6) — $ 1,513 $ 1,425 Recognized as: Inventories $ 1,383 $ 1,315 Other assets 130 110 Inventories valued under the LIFO method 160 105
Schedule of Inventory, Noncurrent	Inventories consisted of: ($ in millions) September 30, 2024 December 31, 2023 Finished goods $ 719 $ 566 Raw materials 26 110 Work in process 697 684 Supplies 77 65 Total (approximates current cost) $ 1,519 $ 1,425 Decrease to last in, first out (“LIFO”) costs (6) — $ 1,513 $ 1,425 Recognized as: Inventories $ 1,383 $ 1,315 Other assets 130 110 Inventories valued under the LIFO method 160 105

Long-Term Debt (Tables)

Long-Term Debt (Tables)	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	The following is a summary of Organon’s total debt: ($ in millions) September 30, 2024 December 31, 2023 Term Loan B Facility: SOFR plus 250 bps term loan due 2031 (1) $ 1,543 $ 2,543 EURIBOR plus 300 bps euro-denominated term loan due 2028 (€726 million in 2024 and €731 million in 2023) 809 809 4.125% secured notes due 2028 2,100 2,100 2.875% euro-denominated secured notes due 2028 (€1.25 billion) 1,394 1,384 5.125% notes due 2031 2,000 2,000 6.750% secured notes due 2034 500 — 7.875% notes due 2034 500 — Other borrowings 8 8 Other (discounts and debt issuance costs) (105) (84) Total principal long-term debt $ 8,749 $ 8,760 Less: Current portion of long-term debt 10 9 Total Long-term debt, net of current portion $ 8,739 $ 8,751 (1) Prior to entering into Amendment No. 2 to the Senior Secured Credit Agreement on May 17, 2024, the maturity date was 2028.
Schedule of Carrying Values and Estimated Fair Values of Debt Instruments	Long-term debt was recorded at the carrying amount. The estimated fair value of long-term debt (including current portion) is as follows: ($ in millions) September 30, 2024 December 31, 2023 Long-term debt $ 8,642 $ 8,253
Schedule of Maturities on Long-term Debt	The schedule of principal payments required on long-term debt for the next five years and thereafter is as follows: ($ in millions) 2024 $ 2 2025 9 2026 10 2027 9 2028 4,277 Thereafter 4,547

Financial Instruments (Tables)

Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Financial Instruments Recorded at Estimated Fair Value	The following financial instruments were recorded at their estimated fair value. The recurring fair value measurement of the assets and liabilities was as follows: ($ in millions) Fair Value Measurement Level September 30, 2024 December 31, 2023 Forward contracts in Other current assets 2 $ 10 $ 9 Forward contracts in Accrued and other current liabilities 2 27 16 Cross-currency swap in Other noncurrent liabilities 2 25 —
Schedule of Long-term Debt Instruments	Foreign currency gain (loss) due to spot rate fluctuations on the euro-denominated debt instruments and the change in fair value of the cross-currency swaps resulting from hedge designation were included within Cumulative translation adjustment in Other comprehensive income (loss): Three Months Ended Nine Months Ended ($ in millions) 2024 2023 2024 2023 Euro-denominated debt instruments (loss) gain $ (92) $ 79 $ (17) $ 21 Cross-currency swaps loss (29) — (25) —
Schedule of (Gain) Loss on Derivative Instruments	The Condensed Consolidated Statements of Income include the impact of net (gains) losses of Organon’s derivative financial instruments: Three Months Ended Nine Months Ended ($ in millions) 2024 2023 2024 2023 Derivative loss (gain) in Exchange losses $ 14 $ (12) $ 5 $ (25) Derivative gain in Interest expense (3) — (5) —

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Schedule of Changes in Accumulated Other Comprehensive Income (Loss) by Component	Changes in Accumulated other comprehensive income (loss) by component are as follows: ($ in millions) Employee Cumulative Accumulated Other Comprehensive (Loss) Income Balance at July 1, 2023, net of taxes $ 9 $ (542) $ (533) Other comprehensive loss, pretax — (43) (43) Tax — — — Other comprehensive loss, net of taxes — (43) (43) Balance at September 30, 2023, net of taxes $ 9 $ (585) $ (576) Balance at July 1, 2024, net of taxes $ (14) $ (598) $ (612) Other comprehensive (loss) income, pretax (1) 42 41 Tax — — — Other comprehensive (loss) income, net of taxes (1) 42 41 Balance at September 30, 2024, net of taxes $ (15) $ (556) $ (571) Balance at January 1, 2023, net of taxes $ 10 $ (574) $ (564) Other comprehensive loss, pretax (1) (11) (12) Tax — — — Other comprehensive loss, net of taxes (1) (11) (12) Balance at September 30, 2023, net of taxes $ 9 $ (585) $ (576) Balance at January 1, 2024, net of taxes $ (15) $ (526) $ (541) Other comprehensive loss, pretax — (30) (30) Tax — — — Other comprehensive loss, net of taxes — (30) (30) Balance at September 30, 2024, net of taxes $ (15) $ (556) $ (571)

Samsung Collaboration (Tables)

Samsung Collaboration (Tables)	9 Months Ended
	Sep. 30, 2024
Revenue from Contract with Customer [Abstract]
Schedule of Information Related to Collaboration	Summarized information related to this collaboration is as follows: Three Months Ended Nine Months Ended ($ in millions) 2024 2023 2024 2023 Sales $ 164 $ 143 $ 499 $ 394 Cost of sales 112 98 329 272 Selling, general and administrative 18 17 60 53 ($ in millions) September 30, 2024 December 31, 2023 Receivables from Samsung included in Other current assets $ 44 $ — Payables to Samsung included in Trade accounts payable 99 104

Third-Party Arrangements (Table

Third-Party Arrangements (Tables)	9 Months Ended
	Sep. 30, 2024
Related Party Transactions [Abstract]
Schedule of Related Party Transactions	The amounts due under such agreements were: ($ in millions) September 30, 2024 December 31, 2023 Due from Merck in Accounts receivable $ 207 $ 583 Due to Merck in Accounts payable 434 619 Sales and cost of sales resulting from the manufacturing and supply agreements with Merck were: Three Months Ended Nine Months Ended ($ in millions) 2024 2023 2024 2023 Sales $ 25 $ 28 $ 82 $ 95 Cost of sales 24 25 76 88

Background and Nature of Oper_2

Background and Nature of Operations (Details)	Sep. 30, 2024 country manufacturingFacility medicineAndProduct product
Product Information [Line Items]
Number of medicines and products | medicineAndProduct	60
Number of manufacturing facilities | manufacturingFacility	6
CANADA
Product Information [Line Items]
Number of biosimilar products | product	5
U.S.
Product Information [Line Items]
Number of biosimilar products | product	3
Oncology Biosimilar
Product Information [Line Items]
Number of countries product sold in | country	20
Immunology Biosimilar
Product Information [Line Items]
Number of countries product sold in | country	5

Acquisitions and Licensing Ar_2

Acquisitions and Licensing Arrangements (Details) - USD ($) $ in Millions	1 Months Ended		2 Months Ended	3 Months Ended		9 Months Ended
	Aug. 31, 2024	Dec. 31, 2023	Sep. 30, 2024	Sep. 30, 2024	Mar. 31, 2024	Sep. 30, 2024	Sep. 30, 2023	Jan. 31, 2024
Asset Acquisition [Line Items]
Acquired in-process research and development and milestones						$ 26	$ 8
Sozhou Centergene Pharmaceuticals
Asset Acquisition [Line Items]
Refundable amount payable			$ 12	$ 12		12
Refundable amount payable to be paid in the next quarter			6	6		6
Commercial milestone payments			170	170		170
Sozhou Centergene Pharmaceuticals | Type B Manufacturing License
Asset Acquisition [Line Items]
Refundable amount payable upon obtaining manufacturing license			6	6		6
Lilly
Asset Acquisition [Line Items]
Upfront payments	$ 23							$ 50
Lilly | Product Rights
Asset Acquisition [Line Items]
Intangible assets acquired			113		$ 220
Contractual upfront payments			23		50
Research and development			90		$ 170
Expected useful life	10 years	10 years
Accrued liabilities			20	20		20
Noncurrent liability			$ 240	240		240
Shanghai Henlius Biotech, Inc. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Asset Acquisition [Line Items]
Research and development				$ 50		70
Acquired in-process research and development and milestones						15
Cirqle Biomedical ("Cirqle") | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Asset Acquisition [Line Items]
Acquired in-process research and development and milestones						$ 10

Earnings per Share (_EPS_) (Det

Earnings per Share (“EPS”) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net income	$ 359	$ 58	$ 755	$ 477
Basic weighted average number of shares outstanding (in shares)	257,498	255,588	256,830	255,112
Stock awards and equity units (share equivalent) (in shares)	2,259	761	2,078	1,050
Diluted weighted average common shares outstanding (in shares)	259,757	256,349	258,908	256,162
EPS:
Basic (in dollars per share)	$ 1.39	$ 0.23	$ 2.94	$ 1.87
Diluted (in dollars per share)	$ 1.38	$ 0.23	$ 2.92	$ 1.86
Share-based Compensation Plans
EPS:
Anti-dilutive shares excluded from the calculation of EPS (in shares)	8,599	10,390	8,587	9,833

Product and Geographic Inform_3

Product and Geographic Information - Narrative (Details)	9 Months Ended
	Sep. 30, 2024 segment
Segment Reporting [Abstract]
Number of operating segments	1

Product and Geographic Inform_4

Product and Geographic Information - Sales of Company's Products (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue from External Customer [Line Items]
Revenues	$ 1,582	$ 1,519	$ 4,811	$ 4,665
Nexplanon/Implanon NXT
Revenue from External Customer [Line Items]
Revenues	243	220	704	599
Follistim AQ
Revenue from External Customer [Line Items]
Revenues	63	54	171	179
NuvaRing
Revenue from External Customer [Line Items]
Revenues	23	43	90	137
Ganirelix Acetate Injection
Revenue from External Customer [Line Items]
Revenues	26	25	82	88
Marvelon/Mercilon
Revenue from External Customer [Line Items]
Revenues	29	30	103	97
Jada
Revenue from External Customer [Line Items]
Revenues	16	13	43	31
Other Women's Health
Revenue from External Customer [Line Items]
Revenues	40	33	119	106
Renflexis
Revenue from External Customer [Line Items]
Revenues	72	69	210	201
Ontruzant
Revenue from External Customer [Line Items]
Revenues	20	40	107	93
Brenzys
Revenue from External Customer [Line Items]
Revenues	27	13	63	45
Aybintio
Revenue from External Customer [Line Items]
Revenues	7	12	22	34
Hadlima
Revenue from External Customer [Line Items]
Revenues	40	8	98	20
Zetia
Revenue from External Customer [Line Items]
Revenues	81	69	240	253
Vytorin
Revenue from External Customer [Line Items]
Revenues	26	33	82	100
Atozet
Revenue from External Customer [Line Items]
Revenues	125	126	396	397
Rosuzet
Revenue from External Customer [Line Items]
Revenues	11	17	36	52
Cozaar/Hyzaar
Revenue from External Customer [Line Items]
Revenues	59	68	186	225
Other Cardiovascular
Revenue from External Customer [Line Items]
Revenues	29	41	99	112
Singulair
Revenue from External Customer [Line Items]
Revenues	85	91	275	290
Nasonex
Revenue from External Customer [Line Items]
Revenues	63	60	200	197
Dulera
Revenue from External Customer [Line Items]
Revenues	48	49	151	144
Clarinex
Revenue from External Customer [Line Items]
Revenues	27	28	100	107
Other Respiratory
Revenue from External Customer [Line Items]
Revenues	14	20	35	52
Arcoxia
Revenue from External Customer [Line Items]
Revenues	69	64	211	207
Fosamax
Revenue from External Customer [Line Items]
Revenues	38	41	112	123
Diprospan
Revenue from External Customer [Line Items]
Revenues	37	31	102	58
Other Non-Opiod Pain, Bone and Dermatology
Revenue from External Customer [Line Items]
Revenues	74	74	227	207
Emgality/Rayvow
Revenue from External Customer [Line Items]
Revenues	29	0	69	0
Proscar
Revenue from External Customer [Line Items]
Revenues	23	25	73	77
Propecia
Revenue from External Customer [Line Items]
Revenues	28	22	79	92
Other
Revenue from External Customer [Line Items]
Revenues	84	76	241	240
Other
Revenue from External Customer [Line Items]
Revenues	26	24	85	102
U.S.
Revenue from External Customer [Line Items]
Revenues	398	370	1,156	1,067
U.S. | Nexplanon/Implanon NXT
Revenue from External Customer [Line Items]
Revenues	172	146	497	418
U.S. | Follistim AQ
Revenue from External Customer [Line Items]
Revenues	26	22	59	74
U.S. | NuvaRing
Revenue from External Customer [Line Items]
Revenues	7	23	33	70
U.S. | Ganirelix Acetate Injection
Revenue from External Customer [Line Items]
Revenues	5	4	16	15
U.S. | Marvelon/Mercilon
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
U.S. | Jada
Revenue from External Customer [Line Items]
Revenues	15	12	42	30
U.S. | Other Women's Health
Revenue from External Customer [Line Items]
Revenues	14	11	41	32
U.S. | Renflexis
Revenue from External Customer [Line Items]
Revenues	56	57	167	172
U.S. | Ontruzant
Revenue from External Customer [Line Items]
Revenues	5	11	23	36
U.S. | Brenzys
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
U.S. | Aybintio
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
U.S. | Hadlima
Revenue from External Customer [Line Items]
Revenues	29	2	71	2
U.S. | Zetia
Revenue from External Customer [Line Items]
Revenues	2	2	5	5
U.S. | Vytorin
Revenue from External Customer [Line Items]
Revenues	1	2	4	5
U.S. | Atozet
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
U.S. | Rosuzet
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
U.S. | Cozaar/Hyzaar
Revenue from External Customer [Line Items]
Revenues	2	3	7	8
U.S. | Other Cardiovascular
Revenue from External Customer [Line Items]
Revenues	0	1	2	2
U.S. | Singulair
Revenue from External Customer [Line Items]
Revenues	2	3	7	8
U.S. | Nasonex
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
U.S. | Dulera
Revenue from External Customer [Line Items]
Revenues	38	40	120	116
U.S. | Clarinex
Revenue from External Customer [Line Items]
Revenues	1	2	2	4
U.S. | Other Respiratory
Revenue from External Customer [Line Items]
Revenues	11	17	26	42
U.S. | Arcoxia
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
U.S. | Fosamax
Revenue from External Customer [Line Items]
Revenues	1	1	3	2
U.S. | Diprospan
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
U.S. | Other Non-Opiod Pain, Bone and Dermatology
Revenue from External Customer [Line Items]
Revenues	5	4	15	11
U.S. | Emgality/Rayvow
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
U.S. | Proscar
Revenue from External Customer [Line Items]
Revenues	0	0	1	1
U.S. | Propecia
Revenue from External Customer [Line Items]
Revenues	2	2	5	5
U.S. | Other
Revenue from External Customer [Line Items]
Revenues	3	5	12	10
U.S. | Other
Revenue from External Customer [Line Items]
Revenues	1	0	(2)	(1)
Int’l
Revenue from External Customer [Line Items]
Revenues	1,184	1,149	3,655	3,598
Int’l | Nexplanon/Implanon NXT
Revenue from External Customer [Line Items]
Revenues	70	74	207	181
Int’l | Follistim AQ
Revenue from External Customer [Line Items]
Revenues	37	32	113	105
Int’l | NuvaRing
Revenue from External Customer [Line Items]
Revenues	17	20	57	67
Int’l | Ganirelix Acetate Injection
Revenue from External Customer [Line Items]
Revenues	20	21	65	74
Int’l | Marvelon/Mercilon
Revenue from External Customer [Line Items]
Revenues	29	30	103	97
Int’l | Jada
Revenue from External Customer [Line Items]
Revenues	0	0	1	0
Int’l | Other Women's Health
Revenue from External Customer [Line Items]
Revenues	28	22	78	74
Int’l | Renflexis
Revenue from External Customer [Line Items]
Revenues	16	12	43	29
Int’l | Ontruzant
Revenue from External Customer [Line Items]
Revenues	15	28	84	57
Int’l | Brenzys
Revenue from External Customer [Line Items]
Revenues	27	13	63	45
Int’l | Aybintio
Revenue from External Customer [Line Items]
Revenues	7	12	22	34
Int’l | Hadlima
Revenue from External Customer [Line Items]
Revenues	11	6	27	18
Int’l | Zetia
Revenue from External Customer [Line Items]
Revenues	80	68	235	248
Int’l | Vytorin
Revenue from External Customer [Line Items]
Revenues	25	31	78	95
Int’l | Atozet
Revenue from External Customer [Line Items]
Revenues	125	126	396	397
Int’l | Rosuzet
Revenue from External Customer [Line Items]
Revenues	11	17	36	52
Int’l | Cozaar/Hyzaar
Revenue from External Customer [Line Items]
Revenues	57	65	179	217
Int’l | Other Cardiovascular
Revenue from External Customer [Line Items]
Revenues	27	39	97	110
Int’l | Singulair
Revenue from External Customer [Line Items]
Revenues	83	88	268	282
Int’l | Nasonex
Revenue from External Customer [Line Items]
Revenues	63	60	200	197
Int’l | Dulera
Revenue from External Customer [Line Items]
Revenues	10	9	31	28
Int’l | Clarinex
Revenue from External Customer [Line Items]
Revenues	26	26	97	103
Int’l | Other Respiratory
Revenue from External Customer [Line Items]
Revenues	3	3	10	10
Int’l | Arcoxia
Revenue from External Customer [Line Items]
Revenues	69	64	211	207
Int’l | Fosamax
Revenue from External Customer [Line Items]
Revenues	37	40	109	121
Int’l | Diprospan
Revenue from External Customer [Line Items]
Revenues	37	31	102	58
Int’l | Other Non-Opiod Pain, Bone and Dermatology
Revenue from External Customer [Line Items]
Revenues	69	70	212	196
Int’l | Emgality/Rayvow
Revenue from External Customer [Line Items]
Revenues	29	0	69	0
Int’l | Proscar
Revenue from External Customer [Line Items]
Revenues	23	25	72	76
Int’l | Propecia
Revenue from External Customer [Line Items]
Revenues	27	21	74	86
Int’l | Other
Revenue from External Customer [Line Items]
Revenues	80	72	229	231
Int’l | Other
Revenue from External Customer [Line Items]
Revenues	$ 26	$ 24	$ 87	$ 103

Product and Geographic Inform_5

Product and Geographic Information - Revenues by Geographic Area (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue from External Customer [Line Items]
Revenues	$ 1,582	$ 1,519	$ 4,811	$ 4,665
Europe and Canada
Revenue from External Customer [Line Items]
Revenues	436	392	1,343	1,259
United States
Revenue from External Customer [Line Items]
Revenues	398	370	1,156	1,067
Asia Pacific and Japan
Revenue from External Customer [Line Items]
Revenues	260	284	806	869
China
Revenue from External Customer [Line Items]
Revenues	212	202	634	661
Latin America, Middle East, Russia, and Africa
Revenue from External Customer [Line Items]
Revenues	243	239	768	687
Other
Revenue from External Customer [Line Items]
Revenues	$ 33	$ 32	$ 104	$ 122

Stock-Based Compensation Plan_2

Stock-Based Compensation Plans - Stock-based Compensation Expenses (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 25	$ 27	$ 79	$ 74
Income tax benefits	6	6	17	16
Cost of sales
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	4	5	13	13
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	17	18	53	50
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 4	$ 4	$ 13	$ 11

Stock-Based Compensation Plan_3

Stock-Based Compensation Plans - Stock Option Valuation Assumptions (Details)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Expected dividend yield	6%	4.82%
Risk-free interest rate	4.12%	3.56%
Expected volatility	41.02%	42.30%
Expected life (years)	5 years 10 months 20 days	5 years 10 months 20 days

Stock-Based Compensation Plan_4

Stock-Based Compensation Plans - Equity Award Transactions (Details) shares in Thousands	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Stock Options
Outstanding, beginning balance (in shares) | shares	5,758,000
Granted/Issued (in shares) | shares	1,503,000
Vested/Exercised (in shares) | shares	0
Forfeited/Cancelled (in shares) | shares	(314,000)
Outstanding, ending balance (in shares) | shares	6,947,000
Weighted average exercise price
Outstanding, beginning balance (in dollars per share)	$ 32.20
Granted (in dollars per share)	18.80
Vested/Exercised (in dollars per share)	0
Forfeited/Cancelled (in dollars per share)	29.11
Outstanding, ending balance (in dollars per share)	29.44
Weighted average grant date fair value
Outstanding, beginning balance (in dollars per share)	8.51
Granted/Issued (in dollars per share)	4.59
Vested/Exercised (in dollars per share)	0
Forfeited/Cancelled (in dollars per share)	7.66
Outstanding, ending balance (in dollars per share)	$ 7.70
RSUs
Shares
Outstanding, beginning balance (in shares) | shares	7,511,000
Granted (in shares) | shares	4,695,000
Vested/Exercised (in shares) | shares	(2,952,000)
Forfeited/Cancelled (in shares) | shares	(864,000)
Outstanding, ending balance (in shares) | shares	8,390,000
Weighted average grant date fair value
Outstanding, beginning balance (in dollars per share)	$ 25.05
Granted (in dollars per share)	18.81
Vested/Exercised (in dollars per share)	29.47
Forfeited/Cancelled (in dollars per share)	21.73
Outstanding, ending balance (in dollars per share)	$ 20.34
PSUs
Shares
Outstanding, beginning balance (in shares) | shares	1,122,000
Granted (in shares) | shares	184,000
Vested/Exercised (in shares) | shares	(56,000)
Forfeited/Cancelled (in shares) | shares	(129,000)
Outstanding, ending balance (in shares) | shares	1,121,000
Weighted average grant date fair value
Outstanding, beginning balance (in dollars per share)	$ 30.16
Granted (in dollars per share)	31.25
Vested/Exercised (in dollars per share)	51.63
Forfeited/Cancelled (in dollars per share)	37.44
Outstanding, ending balance (in dollars per share)	$ 28.44

Stock-Based Compensation Plan_5

Stock-Based Compensation Plans - Equity Awards Outstanding (Details) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares
Equity Awards Vested and Expected to Vest
Stock Options, Awards (in shares) | shares	6,772,000,000
Stock Options, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 29.45
Stock Options, Aggregate Intrinsic Value | $	$ 0
Stock Options, Remaining Term (in years)	6 years 9 months 29 days
Equity Awards That are Exercisable
Stock Options, Awards (in shares) | shares	4,658,000,000
Stock Options, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 33.55
Stock Options, Aggregate Intrinsic Value | $	$ 0
Stock Options, Remaining Term	5 years 8 months 19 days
RSUs
Equity Awards Vested and Expected to Vest
Restricted stock, Awards (in shares) | shares	7,791,000,000
Restricted Stock, Aggregate Intrinsic Value | $	$ 160
Restricted Stock, Remaining Term	1 year 11 months 19 days
PSUs
Equity Awards Vested and Expected to Vest
Restricted stock, Awards (in shares) | shares	854,000,000
Restricted Stock, Aggregate Intrinsic Value | $	$ 18
Restricted Stock, Remaining Term	1 year 6 months 14 days

Stock-Based Compensation Plan_6

Stock-Based Compensation Plans - Narrative (Details) $ in Millions	9 Months Ended
	Sep. 30, 2024 USD ($)
Share-Based Payment Arrangement [Abstract]
Amount of unrecognized compensation costs	$ 160
Amount of unrecognized compensation costs period for recognition	1 year 11 months 12 days

Restructuring - Narrative (Deta

Restructuring - Narrative (Details)	Sep. 30, 2024
Restructuring and Related Activities [Abstract]
Headcount reductions, percent	5%

Restructuring - Schedule of Acc

Restructuring - Schedule of Accrued and Other Current Liabilities (Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Restructuring Reserve [Roll Forward]
Beginning balance	$ 61	$ 20
Severance & severance related costs	23	62
Cash payments and other	(60)	(21)
Ending balance	$ 24	$ 61

Taxes on Income (Details)

Taxes on Income (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Effective income tax rate	(73.70%)	27%	(11.30%)	16.10%
Valuation allowance	$ 210

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Finished goods	$ 719	$ 566
Raw materials	26	110
Work in process	697	684
Supplies	77	65
Total (approximates current cost)	1,519	1,425
Decrease to last in, first out (“LIFO”) costs	(6)	0
Inventory	1,513	1,425
Recognized as:
Inventories	1,383	1,315
Other assets	130	110
Inventories valued under the LIFO method	$ 160	$ 105

Long-Term Debt - Schedule of Lo

Long-Term Debt - Schedule of Long-term Debt Instruments (Details) € in Millions, $ in Millions			9 Months Ended
	May 17, 2024	May 16, 2024	Sep. 30, 2024 USD ($)	Sep. 30, 2024 EUR (€)	Jun. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2023 EUR (€)
Debt Instrument [Line Items]
Other (discounts and debt issuance costs)			$ (105)			$ (84)
Total principal long-term debt			8,749			8,760
Less: Current portion of long-term debt			10			9
Total Long-term debt, net of current portion			8,739			8,751
Notes Payable, Other Payables
Debt Instrument [Line Items]
Long-term debt			8			8
Term Loan B Facility
Debt Instrument [Line Items]
Spread on variable rate	2.50%	3%
Term Loan B Facility | Senior Notes
Debt Instrument [Line Items]
Long-term debt			$ 1,543			2,543
Spread on variable rate			2.50%
Euro Denominated Term Loan B | Senior Notes
Debt Instrument [Line Items]
Long-term debt			$ 809			809
Spread on variable rate			3%
Face amount of debt | €				€ 726			€ 731
4.125% Senior Secured Notes Due 2028 | Senior Notes
Debt Instrument [Line Items]
Long-term debt			$ 2,100			2,100
Stated interest rate			4.125%	4.125%
2.875% Senior Secured Notes Due 2028 | Senior Notes
Debt Instrument [Line Items]
Long-term debt			$ 1,394			1,384
2.875% Senior Secured Notes Due 2028 | Senior Notes | Organon Finance 1 LLC
Debt Instrument [Line Items]
Face amount of debt | €				€ 1,250
Stated interest rate			2.875%	2.875%
5.125% notes due 2031 | Senior Notes
Debt Instrument [Line Items]
Long-term debt			$ 2,000			2,000
5.125% notes due 2031 | Senior Notes | Organon Finance 1 LLC
Debt Instrument [Line Items]
Stated interest rate			5.125%	5.125%
6.750% secured notes due 2034 | Senior Notes
Debt Instrument [Line Items]
Long-term debt			$ 500			0
Face amount of debt					$ 500
Stated interest rate			6.75%	6.75%	6.75%
7.875% notes due 2034 | Senior Notes
Debt Instrument [Line Items]
Long-term debt			$ 500			$ 0
Face amount of debt					$ 500
Stated interest rate					7.875%
7.875% notes due 2034 | Senior Notes | Organon Finance 1 LLC
Debt Instrument [Line Items]
Stated interest rate			7.875%	7.875%

Long-Term Debt - Narrative (Det

Long-Term Debt - Narrative (Details) - USD ($)				1 Months Ended	3 Months Ended	9 Months Ended
	Jun. 26, 2024	May 17, 2024	May 16, 2024	Oct. 31, 2024	Jun. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Debt Instrument [Line Items]
Payment of long-term debt issuance costs						$ 36,000,000	$ 0
Debt instrument interest payments						$ 292,000,000
Average maturity of long-term debt						5 years 6 months
Weighted-average interest rate of debt						5.30%
Revolving Credit Facility
Debt Instrument [Line Items]
Borrowing capacity		$ 300,000,000
Commitment fee percentage		0.375%
Proceeds from lines of credit					$ 36,000,000
Long-term debt						$ 0
Proceeds from revolving credit facility	$ 7,500,000
Revolving Credit Facility | Subsequent Event
Debt Instrument [Line Items]
Proceeds from lines of credit				$ 100,000,000
Senior Notes
Debt Instrument [Line Items]
Payment of long-term debt issuance costs					36,000,000
6.750% secured notes due 2034 | Senior Notes
Debt Instrument [Line Items]
Face amount of debt					$ 500,000,000
Stated interest rate					6.75%	6.75%
Long-term debt						$ 500,000,000		$ 0
7.875% notes due 2034 | Senior Notes
Debt Instrument [Line Items]
Face amount of debt					$ 500,000,000
Stated interest rate					7.875%
Long-term debt						$ 500,000,000		0
Term Loan B Facility
Debt Instrument [Line Items]
Borrowing capacity		$ 1,550,000,000
Spread on variable rate		2.50%	3%
Term Loan B Facility | Senior Notes
Debt Instrument [Line Items]
Spread on variable rate						2.50%
Long-term debt						$ 1,543,000,000		$ 2,543,000,000

Long-Term Debt - Schedule of Ca

Long-Term Debt - Schedule of Carrying Values and Estimated Fair Values of Debt Instruments (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Debt Disclosure [Abstract]
Long-term debt	$ 8,642	$ 8,253

Long-Term Debt - Schedule of Ma

Long-Term Debt - Schedule of Maturities on Long-term Debt (Details) $ in Millions	Sep. 30, 2024 USD ($)
Debt Disclosure [Abstract]
2024	$ 2
2025	9
2026	10
2027	9
2028	4,277
Thereafter	$ 4,547

Financial Instruments - Narrati

Financial Instruments - Narrative (Details) € in Millions, $ in Millions	Sep. 30, 2024 EUR (€)	Sep. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)
Derivative Instruments, Gain (Loss) [Line Items]
Accounts receivables factored | $		$ 39	$ 66
Term Loan B Facility | Senior Notes
Derivative Instruments, Gain (Loss) [Line Items]
Face amount of debt | €	€ 726
2.875% Senior Secured Notes Due 2028 | Senior Notes | Organon Finance 1 LLC
Derivative Instruments, Gain (Loss) [Line Items]
Face amount of debt | €	€ 1,250
Stated interest rate	2.875%	2.875%
Foreign Exchange Forward
Derivative Instruments, Gain (Loss) [Line Items]
Notional amount | $		$ 1,500	$ 1,400
Cross Currency Interest Rate Contract, Euro-Denominated Debt Instruments | 2034 Notes
Derivative Instruments, Gain (Loss) [Line Items]
Derivate fixed interest rate	5.833%	5.833%
Cross Currency Interest Rate Contract, Euro-Denominated Debt Instruments | Euro-Denominated Subsidiaries
Derivative Instruments, Gain (Loss) [Line Items]
Notional amount | €	€ 922
Cross Currency Interest Rate Contract, U.S. Dollar-Denominated Debt Instruments | 2034 Notes
Derivative Instruments, Gain (Loss) [Line Items]
Notional amount | $		$ 1,000
Derivate fixed interest rate	7.3125%	7.3125%

Financial Instruments - Schedul

Financial Instruments - Schedule of Financial Instruments Recorded at Estimated Fair Value (Details) - Level 2 - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Derivative Instruments, Gain (Loss) [Line Items]
Forward contracts in Other current assets	$ 10	$ 9
Forward Contracts
Derivative Instruments, Gain (Loss) [Line Items]
Fair value hedge liabilities	27	16
Cross-currency swaps loss
Derivative Instruments, Gain (Loss) [Line Items]
Fair value hedge liabilities	$ 25	$ 0

Financial Instruments - Sched_2

Financial Instruments - Schedule of Long-term Debt Instruments (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Derivative Instruments, Gain (Loss) [Line Items]
Derivate gain statement of income or comprehensive income extensible enumeration not disclosed flag	Cumulative translation adjustment	Cumulative translation adjustment	Cumulative translation adjustment	Cumulative translation adjustment
Euro-denominated debt instruments (loss) gain
Derivative Instruments, Gain (Loss) [Line Items]
Euro-denominated debt instruments (loss) gain	$ (92)	$ 79	$ (17)	$ 21
Cross-currency swaps loss
Derivative Instruments, Gain (Loss) [Line Items]
Euro-denominated debt instruments (loss) gain	$ (29)	$ 0	$ (25)	$ 0

Financial Instruments - Sched_3

Financial Instruments - Schedule of (Gain) Loss on Derivative Instruments (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Derivative loss (gain) in Exchange losses
Derivative Instruments, Gain (Loss) [Line Items]
Euro-denominated debt instruments (loss) gain	$ 14	$ (12)	$ 5	$ (25)
Derivative gain in Interest expense
Derivative Instruments, Gain (Loss) [Line Items]
Euro-denominated debt instruments (loss) gain	$ (3)	$ 0	$ (5)	$ 0

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	$ 144	$ (555)	$ (70)	$ (892)
Other comprehensive (loss) income, pretax	41	(43)	(30)	(12)
Tax	0	0	0	0
Other comprehensive (loss) income, net of taxes	41	(43)	(30)	(12)
Ending balance	493	(589)	493	(589)
Accumulated Other Comprehensive (Loss) Income
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	(612)	(533)	(541)	(564)
Ending balance	(571)	(576)	(571)	(576)
Employee Benefit Plans
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	(14)	9	(15)	10
Other comprehensive (loss) income, pretax	(1)	0	0	(1)
Tax	0	0	0	0
Other comprehensive (loss) income, net of taxes	(1)	0	0	(1)
Ending balance	(15)	9	(15)	9
Cumulative Translation Adjustment
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	(598)	(542)	(526)	(574)
Other comprehensive (loss) income, pretax	42	(43)	(30)	(11)
Tax	0	0	0	0
Other comprehensive (loss) income, net of taxes	42	(43)	(30)	(11)
Ending balance	$ (556)	$ (585)	$ (556)	$ (585)

Samsung Collaboration - Narrati

Samsung Collaboration - Narrative (Details) $ in Millions	9 Months Ended
	Sep. 30, 2024 USD ($)
Brazil
Disaggregation of Revenue [Line Items]
Gross profit sharing arrangement percentage	35%
Samsung Bioepis
Disaggregation of Revenue [Line Items]
Collaboration agreement period	10 years
Potential future regulatory milestone payments	$ 25
Samsung Bioepis | Brazil
Disaggregation of Revenue [Line Items]
Gross profit sharing arrangement percentage	65%

Samsung Collaboration - Schedul

Samsung Collaboration - Schedule of Information Related to Collaboration (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Disaggregation of Revenue [Line Items]
Sales	$ 1,582	$ 1,519	$ 4,811	$ 4,665
Cost of sales	659	612	1,992	1,832
Selling, general and administrative	422	538	1,290	1,424
Receivables from Samsung included in Other current assets	1,685		1,685		$ 1,744
Payables to Samsung included in Trade accounts payable	1,092		1,092		1,314
Samsung Bioepis
Disaggregation of Revenue [Line Items]
Sales	164	143	499	394
Cost of sales	112	98	329	272
Selling, general and administrative	18	$ 17	60	$ 53
Receivables from Samsung included in Other current assets	44		44		0
Payables to Samsung included in Trade accounts payable	$ 99		$ 99		$ 104

Third-Party Arrangements - Amou

Third-Party Arrangements - Amount Due (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Related Party Transaction [Line Items]
Due from Merck in Accounts receivable	$ 1,685	$ 1,744
Due to Merck in Accounts payable	1,092	1,314
Related Party
Related Party Transaction [Line Items]
Due from Merck in Accounts receivable	207	583
Due to Merck in Accounts payable	$ 434	$ 619

Third-Party Arrangements - Sale

Third-Party Arrangements - Sales and Cost of Sales Resulting from the Manufacturing and Supply Agreements (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Related Party Transaction [Line Items]
Sales	$ 1,582	$ 1,519	$ 4,811	$ 4,665
Cost of sales	659	612	1,992	1,832
Related Party
Related Party Transaction [Line Items]
Sales	25	28	82	95
Cost of sales	$ 24	$ 25	$ 76	$ 88

Contingencies (Details)

Contingencies (Details) $ in Millions	1 Months Ended
	Aug. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Mar. 31, 2014 case	Sep. 30, 2024 USD ($) case	Oct. 13, 2023 USD ($)	Dec. 16, 2022 case	Dec. 15, 2022 case
Loss Contingencies [Line Items]
Amount of legal defense reserves | $		$ 20		$ 17
Fosamax
Loss Contingencies [Line Items]
Number of pending claims				3,085
Fosamax | Federal | Femur Fracture Litigation
Loss Contingencies [Line Items]
Number of pending claims						974	975
Number of claims dismissed			650
Number of claims on appeal			515
Fosamax | New Jersey State Court | Femur Fracture Litigation
Loss Contingencies [Line Items]
Number of pending claims				1,830
Fosamax | California State Court | Femur Fracture Litigation
Loss Contingencies [Line Items]
Number of pending claims				275
Fosamax | Other State Courts | Femur Fracture Litigation
Loss Contingencies [Line Items]
Number of pending claims				4
Implanon | Int’l
Loss Contingencies [Line Items]
Number of pending claims				11
Implanon | Northern District of Ohio
Loss Contingencies [Line Items]
Number of pending claims				2
Number of unfiled claims				56
Nexplanon/Implanon NXT | Int’l
Loss Contingencies [Line Items]
Number of pending claims				21
Nexplanon
Loss Contingencies [Line Items]
Payments for settlements | $	$ 25	$ 35
Accrued loss contingencies | $					$ 20
Nexplanon | Int’l
Loss Contingencies [Line Items]
Number of pending claims				10

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended	9 Months Ended	12 Months Ended
	Oct. 28, 2024	Sep. 30, 2025	Sep. 30, 2024	Jun. 30, 2026	Sep. 30, 2024	Jun. 30, 2026
Dermavant Sciences Ltd
Subsequent Event [Line Items]
Acquisition related costs			$ 4		$ 4
Oss Biotech Site | Forecast
Subsequent Event [Line Items]
Consideration transferred		$ 15		$ 10		$ 25
Subsequent Event | Dermavant Sciences Ltd
Subsequent Event [Line Items]
Upfront payments	$ 175
Subsequent Event | Dermavant Sciences Ltd | Milestone Payment Upon Regulatory Approval
Subsequent Event [Line Items]
Business Combination, Contingent Consideration, Liability	75
Subsequent Event | Dermavant Sciences Ltd | Achievement Of Commercial Milestones, Tiered Royalties On Net Sales, And Assumption Of Liabilities
Subsequent Event [Line Items]
Business Combination, Contingent Consideration, Liability	$ 950